Cell No. : Cell Name
RCB2362 : HS-PSS
update : 2024/08/19
|
Comment | Human cell line derived from malignant peripheral nerve sheath tumor. |
Comment from the depositor | |
Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
Remarks | |
Order Form |
Order Form(C-0005.pdf)
 
MTA(C-0007.pdf)
 
MTA(C-0007p.pdf)
 
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
Basic information
|
Depositor |
Sonobe, Hiroshi
|
Originator |
Sonobe, Hiroshi
|
Year of deposit |
2002
|
Animal |
_human
< Mammals
|
Genus |
Homo
|
Species |
sapiens
|
Gender |
Male
|
Tissue |
prostate
|
Disease name |
malignant peripheral nerve sheath tumour (MPNST)
|
Classification |
cancer
|
|
Lifespan |
infinite
|
Morphology |
other
|
Cellosaurus(Expasy) |
CVCL_8717
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
Culture medium |
|
DMEM (low glucose) + 10% FBS
|
Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
SC frequency |
|
Subculture : once/week, Medium Renewal : 2 times/week
|
Temperature |
|
37
℃
|
CO2 concentration |
|
5
%
|
Freeze medium |
|
Medium + 10% DMSO
|
Freezing method |
|
Slow freezing
|
Mycoplasma/Acholeplasma |
|
(-)
|
Isozyme |
|
LD, NP
|
STR(human) |
|
OK
|
Images |
deposit info | lot info |
|
|
Reference information |
Reference |
0
|
User's Publication |
8
|
User's Publication |
19741
Katayama H, Fujimura A, Huang R, Otani Y, Itano T, Fujiwara T, Kunisada T, Nakata E, Ozaki T.
Role of catecholamine synthases in the maintenance of cancer stem-like cells in malignant peripheral nerve sheath tumors
Cancer Sci
2024
115(3):871-882
PubMed ID: 38279513
DOI: 10.1111/cas.16077
|
21639
Takihira S, Yamada D, Osone T, Takao T, Sakaguchi M, Hakozaki M, Itano T, Nakata E, Fujiwara T, Kunisada T, Ozaki T, Takarada T.
PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours.
Br J Cancer
2024
PubMed ID: 38448751
DOI: 10.1038/s41416-024-02632-8
|
17971
Magallón-Lorenz M, Terribas E, Ortega-Bertran S, Creus-Bachiller E, Fernández M, Requena G, Rosas I, Mazuelas H, Uriarte-Arrazola I, Negro A, Lausová T, Castellanos E, Blanco I, DeVries G, Kawashima H, Legius E, Brems H, Mautner V, Kluwe L, Ratner N, Wallace M, Fernández-Rodriguez J, Lázaro C, Fletcher JA, Reuss D, Carrió M, Gel B, Serra E.
Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis
iScience
2023
26(2):106096
PubMed ID: 36818284
DOI: 10.1016/j.isci.2023.106096
|
20115
Huang R, Fujimura A, Nakata E, Takihira S, Inoue H, Yoshikawa S, Hiyama T, Ozaki T, Kamiya A.
Adrenergic signaling promotes the expansion of cancer stem-like cells of malignant peripheral nerve sheath tumors.
Biochem Biophys Res Commun
2021
557:199-205
PubMed ID: 33872989
DOI: 10.1016/j.bbrc.2021.03.172
|
14763
Kolberg M, Bruun J, Murumägi A, Mpindi JP, Bergsland CH, Høland M, Eilertsen IA, Danielsen SA, Kallioniemi O, Lothe RA.
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors
Mol Oncol
2017
11(9):1156-1171
PubMed ID: 28556483
DOI: 10.1002/1878-0261.12086
|
9577
Tanaka T, Kikuchi N, Goto K, Iino M.
Sec6/8 regulates Bcl-2 and Mcl-1, but not Bcl-xl, in malignant peripheral nerve sheath tumor cells.
Apoptosis
2016
21:594-608
PubMed ID: 26892009
DOI: 10.1007/s10495-016-1230-9
|
17970
Okano M, Sakata N, Ueda S, Takemura T.
Appropriate modulation of autophagy sensitizes malignant peripheral nerve sheath tumor cells to treatment with imatinib mesylate
J Pediatr Hematol Oncol
2014
36(3):200-11
PubMed ID: 24136016
DOI: 10.1097/MPH.0000000000000038
|
17972
Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, Iida K, Matsumoto Y, Hakozaki M, Aoki M, Iwasaki H, Dobashi Y, Nishiyama K, Iwamoto Y, Oda Y.
Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors
Clin Cancer Res
2013
19(2):450-61
PubMed ID: 23209032
DOI: 10.1158/1078-0432.CCR-12-1067
|